Clinical Efficacy Of Edaravone Dexborneol After Intravenous Thrombolysis With Alteplase In The Treatment Of Acute Ischemic Stroke And Its Effect On Hs-CRP,IL-6 And IL-1β

Objective To observe whether the overall outcome of acute cerebral ischemia patients after intravenous thrombolysis with alteplase and intravenous infusion of edaravondexcamphorol for 10±2 days improved compared with conventional therapy.Effects of Edaravonedexhanol on acute ischemic stroke and hs-CRP,IL-6,IL-1β after intravenous thrombolytic therapy with Alteplase.Methods Ninety patients with acute ischemic strokefrom the Central Hospital Affiliated to Shenyang Medical College from December 2021 to December 2022 were selected to receive intravenous thrombolytic therapy with alteplase.rt-PA was used for intravenous thrombolytic therapy at 0.9mg/kg,and the maximum dose was no more than 90 mg according to kg body weight.10% of the calculated total dose of alteplase was administered intravitously within 1 minute,and the remaining dose was administered by micropump at an even rate within 60 minutes.Patients included in the experimental group were randomly divided into experimental group and control group.Patients in the included group were given Edaravondexcamphorol injection 15 ml combined with0.9% sodium chloride injection 100 ml,twice a day,intravenous drip,for 10±2 days.Patients included in the control group were given conventional treatment.The routine treatment of the two groups was based on the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2021",which included anti-platelet aggregation,enhancement of lipid-lowering stable plaque,establishment of collateral circulation,and control of blood pressure,lipids,blood sugar and other factors within the normal range.The clinical efficacy of the patients on the 1st day(before treatment),10±2 days(after treatment),90±7 days(after treatment),National Institutes of Health Stroke Scale score change,modified RANKIN Scale(m RS Score),Barthel Index rating scale were observed.The changes of high-sensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)and interleukin-1β(IL-1β)were measured on day 1(before treatment)and day 10±2(after treatment).To analyze the effects of injection of Edaravandexhanol after alteplase thrombolysis on high sensitive C-reactive protein(hs-CRP),interleukin-6(IL-6),interleukin-1β(IL-1β),nerve function and the mechanism of brain protection in patients with acute ischemic stroke.Results1.Comparison of general data between the two groups showed no statistical significance in the time from onset to admission and smoking(P>0.05);2.There was no significant difference in NIHSS score between the observation group and the control group on day 1 of hospitalization(before treatment)(P>0.05);NIHSS scores of 10±2d and 90±7d after Edaravondexcamphol treatment were lower in observation groups than in control group,and the difference was statistically significant(P<0.05).3.There was no significant difference in m RS Scores between the observation group and the control group on day 1 of hospitalization(before treatment)(P>0.05).The m RS Scores of 10±2d and 90±7d after Edaravonorcamphol treatment were lower in the experimental group than in the control group,and the difference was statistically significant(P<0.05).4.There was no significant difference between the observation group and the control group on the first day of hospitalization(before treatment)in Barthel index score(P>0.05);Barthel index scores of 10±2d and 90±7d after Edaravondexcamphenol treatment were higher in the experimental group than in the control group,and the difference was statistically significant(P<0.05).5.Serum hs-CRP,IL-6 and IL-1β were not significantly different between the two groups on day 1 of hospitalization(before treatment)(P>0.05).Serum hs-CRP,IL-6and IL-1β levels 10±2d after Edaravondexcamphol treatment were lower than those of the control group.The difference was statistically significant(P<0.05).6.Adverse reactions occurred in both groups,8.89% and 6.67%,respectively,with no statistical significance(P>0.05).ConclusionsThe clinical effect of intravenous thrombolysis with alteplase followed by idaravonedexcamphenol was satisfactory in patients with acute ischemic stroke.Edaravond-dexcamphol can inhibit the inflammatory response caused by brain cell injury to a certain extent,relieve the damaged nerve function and improve the ability of daily living.The clinical effect of improving the prognosis of patients is better than that of the control group.Edaravondexcamphorol at therapeutic dose is safe in combination with intravenous thrombolytic therapy and can be used as an effective reference for clinical treatment.